Ketamine and rapidly acting antidepressants: Breaking the speed of sound or light?
Michael Berk, Collen Loo, Christopher G. Davey, Brian H Harvey
Australian & New Zealand Journal of Psychiatry November 2018 DOI: 10.1177/0004867418783567 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Depression Ketamine Esketamine |
| Keywords | Antidepressant Treatment |
Abstract
There is an urgent need for rapidly acting antidepressants. Current therapies share a delayed onset of action, contrasting with drugs of abuse that have rapid psychotropic effects but cause tolerance and dependence. A key uncertainty is whether there is a finite speed limit imposed by the critical role of homeostatic adaptive mechanisms that underpin the efficacy and onset of available psychotropic agents and whether this is mutable with emerging agents with potential rapid onset, in particular ketamine.
Citations in the library
Cites 4
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry 2018
- Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine Current Neuropharmacology March 10, 2016
- Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry January 15, 2010